2025.0715
[News] Publication of Review Result of the 5th Pharmaceutical Reimbursement Evaluation Committee of 2025
Publication of Review Result of the 5th Pharmaceutical Reimbursement Evaluation Committee of 2025
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu)
releases the results of the deliberations of the 5th Pharmaceutical Reimbursement Evaluation Committee in 2025 as follows.
○ Result of the review of the adequacy of the healthcare benefit for the pharmaceutical applied for assessment
Product
Pharmaceutical company
Efficacy and effectiveness
Deliberation results
Besremi Inj.
(Ropeginterferon alfa-2b, Recombinant DNA)
PharmaEssentia Korea Co., Ltd.
Treatment of patients with polycythemia vera
Reimbursement is adequate
Jaypirca Tab. 50mg, 100mg
(Pirtobrutinib)
Eli Lilly Korea Ltd.
Relapsed or refractory mantle cell lymphoma (MCL)
Reimbursement is adequate*
* Subject to the submission of supporting documents by the pharmaceutical company in the future.
○ Evaluation results of the expanded scope of use for risk-sharing agreement pharmaceutical
Product
Pharmaceutical company
Efficacy and effectiveness
Deliberation results
Darzalex Inj.
(Daratumumab)
Janssen Korea Co., Ltd.
Multiple Myeloma
Reimbursement is adequate
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The final evaluation results may be subject to change if there are changes in the detailed reimbursement scope and items of the drug, changes in the approval of the item applied for decision, or revocation (cancellation) of the approval.
